Hematopoiesis News 7.39 October 4, 2016 | |
| |
TOP STORYResearchers sought to delineate the molecular mechanisms by which cohesin mutations promote enhanced hematopoietic stem and progenitors self-renewal as this represents a critical initial step during leukemic transformation. [Leukemia] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)The authors report that genetic inactivation of Zeb2 results in increased frequency of stem and progenitor subpopulations within the bone marrow and spleen and that these changes accompany differentiation defects in multiple hematopoietic cell lineages. They found no evidence that Zeb2 is critical for hematopoietic stem cell self-renewal capacity. [Blood] Abstract Investigators developed a synthetic three-dimensional hematopoietic niche system comprising nanofibers seeded with bone marrow-derived stromal cells and growth factors to induce functional hematopoietic cells from human-induced pluripotent stem cells in vitro. [J Hematol Oncol] Full Article Loss of Dnmt3a Induces CLL and PTCL with Distinct Methylomes and Transcriptomes in Mice Using high resolution global methylation and expression analysis investigators showed that whereas patterns of methylation and transcription in normal B-1a cells and CD8-positive T cells are similar, methylomes and transcriptomes in malignant B-1a and CD8+ T cells are remarkably distinct, suggesting a cell-type specific function for Dnmt3a in cellular transformation. [Sci Rep] Full Article CLINICAL RESEARCHLong-Term Outcome of Six-Month Maintenance Chemotherapy for Acute Lymphoblastic Leukemia in Children Scientists aimed to confirm the long-term outcome of L92-13, and to identify who can or cannot be cured by shorter duration of maintenance therapy. To obtain sentinel cytogenetics information which had been missed before, they performed genetic analysis with genomic microarray and target intron-capture sequencing from diagnostic bone marrow smear. [Leukemia] Abstract This study assessed the impact of baseline cytogenetics on the outcomes of 428 adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia who were receiving frontline chemotherapy. Three hundred thirty patients were treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone-based regimens, and ninety eight were treated with the augmented Berlin-Frankfurt-Munster regimen. [Cancer] Abstract Whereas previous studies employed Sanger sequencing, scientists used next generation amplicon deep sequencing for in depth evaluation of RAS mutations in 36 pediatric patients at diagnosis of MLL-AF4+ leukemia. RAS mutations including those in small sub-clones were detected in 63.9% of patients. [Sci Rep] Full Article The authors retrospectively analyzed patients with localized primary gastric-diffuse large B-cell lymphoma who were initially treated with a rituximab-containing regimen, with a focus on the status of MYC and BCL2. [Blood Cancer J] Full Article High-dose melphalan and autologous stem cell transplantation (HDM/ASCT) is widely used in immunoglobulin light chain (AL) amyloidosis, but the benefit is debated mainly because of the high treatment-related mortality. The investigators report on the long-term outcome of all patients treated with HDM/ASCT for AL amyloidosis in Sweden between 1994 and 2009. [Bone Marrow Transplant] Abstract | |
| |
REVIEWSTranslating Leukemia Stem Cells into the Clinic: Harmonizing the Heterogeneity Considerable evidence suggests that rare leukemia cells with stem cell features, including self-renewal capacity and drug resistance, are primarily responsible for both disease maintenance and relapses. Traditionally, these so-called leukemia stem cells have been identified in the laboratory by their ability to engraft acute myeloid leukemia into immunocompromised mice. [Exp Hematol] Abstract Visit our reviews page to see a complete list of reviews in the hematopoiesis research field. | |
| |
INDUSTRY NEWSDr. Allen Eaves of STEMCELL Technologies Inc. Named EY Entrepreneur Of The Yearâ„¢ Pacific 2016 Dr. Allen Eaves, Chairman, President and Chief Executive Officer of STEMCELL Technologies, a global biotechnology company that supplies tools and services to enable life science research, is this year’s Entrepreneur Of The Year Pacific winner. [Ernst & Young (CNW Group Ltd.)] Press Release Amgen announced top-line results of the Phase III CLARION trial, which evaluated an investigational regimen of KYPROLIS®, melphalan and prednisone versus Velcade® (bortezomib), melphalan and prednisone for 54 weeks in patients with newly diagnosed multiple myeloma who were ineligible for hematopoietic stem-cell transplant. The trial did not meet the primary endpoint of superiority in progression-free survival. [Amgen] Press Release SkylineDx announced it has been awarded a multi-million euro Horizon2020 grant from the European Commission to develop a new, and novel gene-expression profiling technology, which is intended to predict the most effective treatment strategy for patients with multiple myeloma. [SkylineDx (PR Newswire Association LLC)] Press Release Jazz Pharmaceuticals plc announced the initiation of a rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration on September 30, 2016, seeking marketing approval of Vyxeosâ„¢ (cytarabine and daunorubicin liposome injection), an investigational agent for the treatment of acute myeloid leukemia. [Jazz Pharmaceuticals plc] Press Release | |
| |
POLICY NEWSDemocratic Databases: Science on GitHub Scientists are turning to a software–development site to share data and code. [Nature Toolbox] Editorial UK Bioethicists Eye Designer Babies and CRISPR Cows From designer babies to engineered mosquitoes, advances in genome-editing technologies such as CRISPR–Cas9 have raised the possibility of tremendous scientific advances — and serious ethical concerns. [Nature News] Editorial Biologists Plan Scoring System for Antibodies Biomedical experts plan to create a scoring system that will help researchers choose reliable antibodies for their experiments. The only problems: figuring out how such a ranking would work — and getting manufacturers to adopt the standard. [Nature News] Editorial
| |
EVENTSNEW 2016 World Cancer Congress NEW Advances in Cell Engineering, Imaging and Screening Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESResearch Technologist – Hematopoietic Product Development (STEMCELL Technologies) Research Associate – Hematology (Editas Medicine) Faculty – Stem Cell Transplantation and Regenerative Medicine (Stanford University Medical School) Postdoctoral Position – Hematology and Gene Therapy (Cincinnati Children’s Research Foundation) Postdoctoral Position – Leukemia and Marrow Failure (H. Leighton Grimes) Assistant Associate/Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center) Research Fellow – Cancer Biology (University of Michigan) PhD – Tumor Microenvironment in Leukemia (Georg-Speyer-Haus) Postdoctoral Scholar – Tumor Biology (The Pennsylvania State University College of Medicine) Research Technologist (Pennsylvania State University) Postdoctoral Research Scientist (National Taiwan University) Assistant Member Faculty – Platinum/Immunotherapy (Fred Hutchinson Cancer Research Center) Cytogenetics Laboratory Supervisor (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Hematopoiesis News Volume 7.39 | Oct 4 2016